Fujifilm Corporation (Tokyo, Japan) has announced that its software for analyzing chest X-ray developed with the core artificial intelligence (AI) technology of Lunit (Seoul, Korea) will be commercially available across Japan.
The AI-powered product named CXR-AID is designed to better detect major abnormal findings such as chest nodule, consolidation, and pneumothorax from chest X-ray images. Findings detected by the AI software are shown in color as a heatmap display, with each score included. Through this solution, doctors and medical professionals are able to reduce missed cases and effectively diagnose chest diseases from chest X-ray.
The PMDA approved AI-powered software is developed with Lunit’s core AI technology and is provided with Fujifilm's PACS system(SYNAPSE) and to be distributed across hospitals and medical institutions of Japan for more efficient diagnosis. With Lunit AI connected to Fujifilm's PACS system and X-ray devices, the AI products are distributed across its global customers and networks.
Lunit AI is also applied in Fujifilm's mobile X-ray device (FDR nano) and portable X-ray devices (FDR Xair), General X-ray device (FDR Smart X), and is in use in clinical settings to detect COVID-19 symptoms and tuberculosis in regions where there are a limited number of doctors.
"We strongly believe that sooner or later AI will become the new standard of care, and AI will be used everywhere as a must-use product," said Brandon Suh, CEO of Lunit. "Not only will it be used as a tool to make the workflow more efficient, but it will ensure better diagnosis and healthier life for patients. We are glad to make this happen with Fujifilm, and will accelerate our expansion with its global network."